Iovance Biotherapeutics Inc to Discuss Updates for the C-144-01 Clinical Study Transcript
Thank you for standing by, and welcome to the Iovance Biotherapeutics Update Call. (Operator Instructions) As a reminder, today's call is being recorded.
I would now like to turn the conference to your host for today, Ms. Sara Pellegrino. Ma'am, you may begin.
Thank you, operator. Good evening, and thank you for joining us to discuss the positive clinical data for lifileucel to support our upcoming planned BLA submission in metastatic melanoma. During today's call, Dr. Fred Vogt, our Interim President and Chief Executive Officer, will provide a brief introduction; and Dr. Friedrich Finckenstein, our Chief Medical Officer, will further highlight the results from the C-144-01 melanoma study. Following these updates, we will hold a Q&A session. Additional Iovance team members taking part in the Q&A include Jean-Marc Bellemin, our Chief Financial Officer; Dr. Igor Bilinsky, our Chief Operating Officer; Dr. Madan Jagasia, SVP of Medical Affairs; Dr. Raj Puri, our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |